Bella - I’d suggest their strategy is to leave a bit on the table going into results. It could go either way for them, and they’ve made a bit up up now.
Apologies if already posted. I can’t remember seeing the AVA data presented in this way. Slide 29 explicitly states a mouse XENOGRAFT model was used in the study, with the results being superb, as we now know in context.
Begs the question; why has AS been so quiet for so long?? I’d guess the wait is ensuring this study is as conclusive as possible, providing enough clues to predict efficacy.
Yes, sorry, I realised it was a preso. Either way, difficult to understand why they’ve communicated it as market sensitive? Post Covid raise, he’s been rather selective.
Still trying to work out why they would RNS presentation literature. We’ve had regulatory applications that have been kept under wraps, yet they chose to make a big deal out of this?
Are they likely to present info that is market sensitive? I’m certainly buying the ‘it works’ brand that is being peddled. But; there must be something ‘new’ to shout about??
It looks set to build into next weeks results I think. Holding after that will be the acid test. It’s been a nice couple of days :) watching the spike as always.
Belgrano - it has not delivered. The can has been booted across the Atlantic.
TW will say what he feels necessary to support his trading activity. He’s allegedly been exposed multiple times employing trolls to talk down a company. Beware.